Dopaminergic pathways

Pathways {{anchor|Mesocorticolimbic projection}}

Major

Six of the dopaminergic pathways are listed below.

Minor

:Hypothalamospinal :* Hypothalamus → Spinal cord :Incertohypothalamic :* Zona incerta → Hypothalamus :* Zona incerta → Brainstem VTA → Amygdala (mesoamygdaloid pathway) :VTA → Hippocampus :VTA → Cingulate cortex :VTA → Olfactory bulb :SNc → Subthalamic nucleus

Function

Mesocorticolimbic system

The mesocorticolimbic system (mesocorticolimbic circuit) refers to both the mesocortical and mesolimbic pathways. Both pathways originate at the ventral tegmental area (VTA) which is located in the midbrain. Through separate connections to the prefrontal cortex (mesocortical) and ventral striatum (mesolimbic), the mesocorticolimbic projection has a significant role in learning, motivation, reward, memory and movement. Dopamine receptor subtypes, D1 and D2 have been shown to have complementary functions in the mesocorticolimbic projection, facilitating learning in response to both positive and negative feedback. Both pathways of the mesocorticolimbic system are associated with ADHD, schizophrenia and addiction.

Mesocortical pathway

The mesocortical pathway projects from the ventral tegmental area to the prefrontal cortex (VTA → Prefrontal cortex). This pathway is involved in cognition and the regulation of executive functions (e.g., attention, working memory, inhibitory control, planning, etc.) This intricate neural circuit serves as a crucial communication route within the brain, facilitating the transmission of dopamine, a neurotransmitter associated with reward, motivation, and cognitive control. The prefrontal cortex, being a central hub for executive functions, relies on the input from the mesocortical pathway to modulate and fine-tune cognitive processes essential for goal-directed behavior and decision-making. Dysregulation of the neurons in this pathway has been connected to ADHD.

Mesolimbic pathway

Referred to as the reward pathway, mesolimbic pathway projects from the ventral tegmental area to the ventral striatum (VTA → Ventral striatum [nucleus accumbens and olfactory tubercle]). When a reward is anticipated, the firing rate of dopamine neurons in the mesolimbic pathway increases. The mesolimbic pathway is involved with incentive salience, motivation, reinforcement learning, fear and other cognitive processes. In animal studies, depletion of dopamine in this pathway, or lesions at its site of origin, decrease the extent to which an animal is willing to go to obtain a reward (e.g., the number of lever presses for nicotine or time searching for food). Research is ongoing to determine the role of the mesolimbic pathway in the perception of pleasure.

Nigrostriatal pathway

The nigrostriatal pathway is involved in behaviors relating to movement and motivation. The transmission of dopaminergic neurons to the dorsal striatum particularly plays a role in reward and motivation while movement is influenced by the transmission of dopaminergic neurons to the substantia nigra. The nigrostriatal pathway is associated with conditions such as Huntington's disease, Parkinson's disease, ADHD, Schizophrenia, and Tourette's Syndrome. Huntington's disease, Parkinson's disease, and Tourette's Syndrome are conditions affected by motor functioning while schizophrenia and ADHD are affected by reward and motivation functioning. This pathway also regulates associated learning such as classical conditioning and operant conditioning.

Tuberoinfundibular pathway

The tuberoinfundibular pathway transmits dopamine from the hypothalamus to the pituitary gland. This neural circuit plays a pivotal role in the regulation of hormonal balance and, specifically, in modulating the secretion of prolactin from the pituitary gland, which is responsible for breast milk production in females. Hyperprolactinemia is an associated condition caused by an excessive amount of prolactin production that is common in pregnant women. After childbirth, the tuberoinfundibular pathway resumes its role in regulating prolactin levels. The decline in estrogen levels postpartum contributes to the restoration of dopaminergic inhibition, preventing sustained hyperprolactinemia in non-pregnant and non-nursing individuals.

Cortico-basal ganglia-thalamo-cortical loop

The dopaminergic pathways that project from the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) into the striatum (i.e., the nigrostriatal and mesolimbic pathways, respectively) form one component of a sequence of pathways known as the cortico-basal ganglia-thalamo-cortical loop. The nigrostriatal component of the loop consists of the SNc, giving rise to both inhibitory and excitatory pathways that run from the striatum into the globus pallidus, before carrying on to the thalamus, or into the subthalamic nucleus before heading into the thalamus. The dopaminergic neurons in this circuit increase the magnitude of phasic firing in response to positive reward error, that is when the reward exceeds the expected reward. These neurons do not decrease phasic firing during a negative reward prediction (less reward than expected), leading to hypothesis that serotonergic, rather than dopaminergic neurons encode reward loss. Dopamine phasic activity also increases during cues that signal negative events, however dopaminergic neuron stimulation still induces place preference, indicating its main role in evaluating a positive stimulus. From these findings, two hypotheses have developed, as to the role of the basal ganglia and nigrostriatal dopamine circuits in action selection. The first model suggests a "critic" which encodes value, and an actor which encodes responses to stimuli based on perceived value. However, the second model proposes that the actions do not originate in the basal ganglia, and instead originate in the cortex and are selected by the basal ganglia. This model proposes that the direct pathway controls appropriate behavior and the indirect suppresses actions not suitable for the situation. This model proposes that tonic dopaminergic firing increases the activity of the direct pathway, causing a bias towards executing actions faster.

These models of the basal ganglia are thought to be relevant to the study of OCD, ADHD, Tourette syndrome, Parkinson's disease, schizophrenia, and addiction. For example, Parkinson's disease is hypothesized to be a result of excessive inhibitory pathway activity, which explains the slow movement and cognitive deficits, while Tourettes is proposed to be a result of excessive excitatory activity resulting in the tics characteristic of Tourettes.

Regulation

The ventral tegmental area and substantia nigra pars compacta receive inputs from other neurotransmitters systems, including glutaminergic inputs, GABAergic inputs, cholinergic inputs, and inputs from other monoaminergic nuclei. The VTA contains 5-HT1A receptors that exert a biphasic effects on firing, with low doses of 5-HT1A receptor agonists eliciting an increase in firing rate, and higher doses suppressing activity. The 5-HT2A receptors expressed on dopaminergic neurons increase activity, while 5-HT2C receptors elicit a decrease in activity. The mesolimbic pathway, which projects from the VTA to the nucleus accumbens, is also regulated by muscarinic acetylcholine receptors. In particular, the activation of muscarinic acetylcholine receptor M2 and muscarinic acetylcholine receptor M4 inhibits dopamine release, while muscarinic acetylcholine receptor M1 activation increases dopamine release. GABAergic inputs from the striatum decrease dopaminergic neuronal activity, and glutaminergic inputs from many cortical and subcortical areas increase the firing rate of dopaminergic neurons. Endocannabinoids also appear to have a modulatory effect on dopamine release from neurons that project out of the VTA and SNc. Noradrenergic inputs deriving from the locus coeruleus have excitatory and inhibitory effects on the dopaminergic neurons that project out of the VTA and SNc. The excitatory orexinergic inputs to the VTA originate in the lateral hypothalamus and may regulate the baseline firing of VTA dopaminergic neurons.

Notes

References

References

1. (December 2007). "Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective". Brain Research Reviews.
2. "Beyond the Reward Pathway". University of Utah.
3. (1995). "Psychopharmacology: the fourth generation of progress". Raven Press.
4. (2008). "Handbook of Neurochemistry and Molecular Neurobiology". Springer US.
5. (2009). "Molecular Neuropharmacology: A Foundation for Clinical Neuroscience". McGraw-Hill Medical.
6. (November 2010). "Brain reward circuitry beyond the mesolimbic dopamine system: a neurobiological theory". Neuroscience and Biobehavioral Reviews.
7. (2017). "Hormones, Brain and Behavior". Elsevier.
8. (2017). "Reference Module in Neuroscience and Biobehavioral Psychology". Elsevier.
9. (2012). "Neurobiology of Psychiatric Disorders". Elsevier.
10. (2009). "Molecular Neuropharmacology: A Foundation for Clinical Neuroscience". McGraw-Hill Medical.
11. (October 2004). "Synaptic release of dopamine in the subthalamic nucleus". The European Journal of Neuroscience.
12. (October 2013). "Potential substrates for nicotine and alcohol interactions: a focus on the mesocorticolimbic dopamine system". Biochemical Pharmacology.
13. (June 2011). "Mesocorticolimbic glutamatergic pathway". The Journal of Neuroscience.
14. (December 2019). "Differential contributions of striatal dopamine D1 and D2 receptors to component processes of value-based decision making". Neuropsychopharmacology.
15. (2009). "Molecular Neuropharmacology: A Foundation for Clinical Neuroscience". McGraw-Hill Medical.
16. (December 2008). "Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate". Current Neuropharmacology.
17. (December 2010). "New insights into the roles of microRNAs in drug addiction and neuroplasticity". Genome Medicine.
18. (October 2011). "Transcriptional and epigenetic mechanisms of addiction". Nature Reviews. Neuroscience.
19. Keyser, J. De. (1990). "The mesoneocortical dopamine neuron system". Neurology.
20. (2006). "Mesocortical dopamine modulation of executive functions: beyond working memory". Psychopharmacology.
21. (November 2012). "The mysterious motivational functions of mesolimbic dopamine". Neuron.
22. (December 2004). "Mesolimbic dopaminergic pathways in fear conditioning". Progress in Neurobiology.
23. (May 2015). "Pleasure systems in the brain". Neuron.
24. (June 2013). "Neuroscience of affect: brain mechanisms of pleasure and displeasure". Current Opinion in Neurobiology.
25. (2020). "Molecular neuropharmacology a foundation for clinical neuroscience".
26. (May 2015). "Pleasure systems in the brain". Neuron.
27. (August 2007). "The role of the dorsal striatum in reward and decision-making". The Journal of Neuroscience.
28. (2018). "Physiological and Functional Basis of Dopamine Receptors and Their Role in Neurogenesis: Possible Implication for Parkinson's disease". Journal of Experimental Neuroscience.
29. (2016-09-09). "Meta-Analysis of Parkinson's Disease Transcriptome Data Using TRAM Software: Whole Substantia Nigra Tissue and Single Dopamine Neuron Differential Gene Expression". PLOS ONE.
30. (2017). "Learning and Memory: A Comprehensive Reference". Elsevier.
31. (2021-08-01). "Perioperative pain management and outcomes in patients who -discontinued or continued pre-existing buprenorphine therapy". Journal of Opioid Management.
32. (2001). "The Maternal Brain".
33. (2013). "The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans". Substance Abuse and Rehabilitation.
34. (August 2015). "The ins and outs of the striatum: role in drug addiction". Neuroscience.
35. Roberts, Angela C.. (June 2011). "The Importance of Serotonin for Orbitofrontal Function". Biological Psychiatry.
36. (February 2011). "From reinforcement learning models to psychiatric and neurological disorders". Nature Neuroscience.
37. (June 2013). "Abnormally high degree connectivity of the orbitofrontal cortex in obsessive-compulsive disorder". JAMA Psychiatry.
38. (1 January 2008). "The neural bases of obsessive-compulsive disorder in children and adults". Development and Psychopathology.
39. (January 2010). "Handbook of Behavioral Neuroscience". Academic.
40. (June 2015). "Muscarinic regulation of dopamine and glutamate transmission in the nucleus accumbens". Proceedings of the National Academy of Sciences of the United States of America.
41. (December 2007). "Endocannabinoid signaling in midbrain dopamine neurons: more than physiology?". Current Neuropharmacology.
42. (December 2011). "Dynamic regulation of midbrain dopamine neuron activity: intrinsic, synaptic, and plasticity mechanisms". Neuroscience.
43. (2014). "New perspectives on catecholaminergic regulation of executive circuits: evidence for independent modulation of prefrontal functions by midbrain dopaminergic and noradrenergic neurons". Frontiers in Neural Circuits.
44. (December 2013). "Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far". Frontiers in Neuroscience.
45. (February 2010). "Lateral hypothalamic orexin/hypocretin neurons: A role in reward-seeking and addiction". Brain Research.
46. (March 2014). "Human orexin/hypocretin receptors form constitutive homo- and heteromeric complexes with each other and with human CB1 cannabinoid receptors". Biochemical and Biophysical Research Communications.